|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Imatinib>> Market Analysis Reports |
Market Analysis Reports of Imatinib |
|
Imatinib free base (CAS 152459-95-5) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Alpha-IMATINIB MESYLATE (CAS 220127-57-1) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Imatinib mesylate / Gleevec (CAS 220127-57-1) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Imatinib mesylate (CAS 152549-95-5) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Imatinib Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). 4-Methyl-N3-[4-(3-pyridinyl)-2-pyrimidinyl]-1,3-benzenediamine (CAS 152460-10-1) Market Research Report 2025 BAC Reports offers its clients in-depth market research of chemical industry products on the global and regional markets (North & Latin America, Asia Pacific, European Union, Russia and CIS). Global Market Report of Imatinib (CAS 152459-95-5) December 2024 Global Imatinib Drug Market Size study & Forecast, by Drug Formulation (Capsules, Tablets) by Application Type (Philadelphia Positive Chronic Myeloid Leukemia, Hyper-Eosinophilic Syndrome (HES), Myelodysplastic Syndrome (MDS), Myeloproliferative Diseases (MPD), Gastrointestinal Stromal Tumors (GIST), Others) and Regional Analysis, 2023-2030 ... in the gastrointestinal tract. The Imatinib Drug market is expanding because ... and increasing R&D activities related to imatinib drug development is creating a lucrative ... application for a novel formulation of imatinib. Global Imatinib Drug Market Report ... Investigation Report on Chinese Imatinib Market, 2018-2022 ... of Imatinib in China Development of generic Imatinib in China India-made Imatinib smuggled to China Prospects of Chinese Imatinib ... Investigation Report on China Imatinib Mesylate Market, 2010-2019 ... inhibitor developed by Novartis. On May. 10, 2001, Imatinib Mesylate got FDA’s express approval ... report: market size of Imatinib Mesylate in China major manufacturers of Imatinib Mesylate in the Chinese ... Novartis AG Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... a diuretic. Oncology Gleevec/Glivec (imatinib mesylate tablets/imatinib): It is a signal transduction inhibitor approved ... Global Market Report of Imatinib (Piperidine)-N-oxide (CAS 571186-91-9) December 2024 Global Market Report of Imatinib (Pyridine)-N-oxide (CAS 571186-92-0) December 2024 Global Market Report of N-Desmethyl Imatinib (CAS 404844-02-6) December 2024 Global Market Report of Imatinib mesylate (CAS 220127-57-1) December 2024 Bristol-Myers Squibb Company Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... or intolerance to prior therapy, including GLEEVEC (imatinib mesylate), and for the treatment ... Chemgenex Pharmaceuticals Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... the tyrosine kinase inhibitor (TKI) imatinib and have the T315I point ... Jupiter Bioscience Ltd. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... infertility treatment and prostrate cancer; Imatinib for the treatment of Leukemia and ... Moneylogix Group, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... expression for chronic myelogenous leukemia to imatinib. Moneylogix Group plans to market and ... Pfizer Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... (GIST) after disease progression on, or intolerance to, imatinib mesylate. Xalatan, a prostaglandin, is the branded ... |